Myelofibrosis (MF)
Hematology·MeSH: Primary Myelofibrosis
Prevalence
5.0 / 100K
3 drugs in development·3 companies·4 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| navitoclax | AbbVie Inc. (ABBV) |
Phase 2(1)
Preclinical(1)
| Drug | Company |
|---|---|
| dmr-001 | Damora Therapeutics, Inc. (DMRA) |
Compare drugs
Frequently asked questions
How many drugs are in development for Myelofibrosis (MF)?
BioSniper tracks 3 drugs in development for Myelofibrosis (MF) across 3 companies.
How many clinical trials target Myelofibrosis (MF)?
There are 4 clinical trials targeting Myelofibrosis (MF) tracked by BioSniper.
What is the prevalence of Myelofibrosis (MF)?
The estimated prevalence of Myelofibrosis (MF) is approximately 5.0 per 100,000 population.
Deep-dive into Myelofibrosis (MF)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis